Related Experiment Video
Updated: May 12, 2026

Important Endpoints and Proliferative Markers to Assess Small Intestinal Injury and Adaptation using a Mouse Model of Chemotherapy-Induced Mucositis
Published on: May 12, 2019
Low molecular weight chitosan accelerates glucagon-like peptide-1 secretion in human intestinal endocrine cells via a
Shing Hwa Liu1, Ya Wen Huang, Cheng Tien Wu
1Institute of Toxicology, College of Medicine, National Taiwan University, Taipei, Taiwan.
Abstract:
Chitosan is widely employed as a dietary supplement. Several studies have shown that chitosan possesses an antidiabetic effect. An important intestinal incretin hormone, glucagon-like peptide-1 (GLP-1), is also known to contribute to the amelioration of diabetes. This study investigated whether chitosan possesses an ability in GLP-1 synthesis and secretion in human intestinal cells. Low molecular weight chitosan (LMWC) significantly increases GLP-1 secretion in human intestinal endocrine cells (NCI-H716) in a dose-dependent manner. LMWC could also dose-dependently increase the mRNA expression of proglucagon, a GLP-1 precursor, but did not affect prohormone convertase 3 (PC 3) mRNA expression. LMWC effectively increased the phosphorylation of mitogen-activated protein kinases (MAPK)-p38 and c-Jun N-terminal kinases (JNK), but not extracellular-signal-regulated kinases (ERK). An inhibitor of p38, but not JNK and ERK, significantly reversed the LMWC-increased proglucagon expression. Taken together, LMWC accelerates proglucagon expression and GLP-1 secretion through a p38/MAPK-dependent signaling pathway. These findings suggest that LMWC may provide a strategy for diabetes therapy.
More Related Videos
09:16Mixed Primary Cultures of Murine Small Intestine Intended for the Study of Gut Hormone Secretion and Live Cell Imaging of Enteroendocrine Cells
Published on: April 20, 2017
07:00Mechanisms Underlying Gut Hormone Secretion Using the Isolated Perfused Rat Small Intestine
Published on: February 26, 2019
Related Concept Videos
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
Insulin and C-peptide are co-secreted in...
Hormonal Regulation
Glucose Absorption Into the Small Intestine
Cell Specific Gene Expression
Insulin Secretory Vesicles